Results 181 to 190 of about 159,852 (315)
Objective To characterize the clinical, immunologic, and proteomic changes associated with CD19 chimeric antigen receptor T cell therapy in patients with progressive systemic sclerosis (SSc). Methods Patients with progressive SSc received CD19 chimeric antigen receptor (CAR)‐T cell therapy and were observed longitudinally for safety, clinical efficacy,
Chenhan Jia +16 more
wiley +1 more source
Towards biology-informed therapies for long COVID. [PDF]
eBioMedicine.
europepmc +1 more source
Expert Perspectives: Defining and Managing Progressive Pulmonary Fibrosis in Systemic Sclerosis
Systemic sclerosis–associated interstitial lung disease (SSc‐ILD) is one of the leading causes of morbidity and mortality in SSc, affecting up to three‐quarters of patients. The disease course is highly heterogeneous, ranging from indolent, nonprogressive forms to rapidly progressive pulmonary fibrosis (PPF).
Devis Benfaremo +7 more
wiley +1 more source
Antigen Microarray Reveals Broad and Subclinical Autoimmunity in Patients with Inborn Errors of Immunity. [PDF]
Zhang W +10 more
europepmc +1 more source
Objective Anti‐homocitrullinated protein/peptide antibodies are specific to rheumatoid arthritis (RA) and predictive of worse prognosis, suggesting a pathogenic role for autoreactivity to homocitrullinated peptides (HomoCitP). However, T cell responses to HomoCitP remain largely unexplored.
Sofya Ulanova +6 more
wiley +1 more source
Non-Conventional and Emerging Autoantibodies in Sjögren’s Disease
Adrian YS Lee1,2 1Department of Clinical Immunology & Allergy, Westmead Hospital & ICPMR, Sydney, NSW, Australia; 2Centre for Immunology & Allergy Research, Westmead Institute for Medical Research, The University of Sydney, Sydney, NSW ...
Lee AYS
doaj
Absence of autoantibodies linked to cancer and autoimmune disorders 26 weeks after BNT162b2 boosting in CoronaVac- primed individuals. [PDF]
Mat Yassim AS +6 more
europepmc +1 more source
From Interferon Signature to the Clinical Landscape: Type I Interferonopathies
Background Type I interferonopathies are heterogeneous diseases driven by dysregulated IFN‐I signaling. Diagnosis is challenging due to clinical/molecular variability and the need for IFN‐I quantification. Objective To characterize the clinical, immunological, genetic, molecular profiles of patients with suspected enhanced IFN‐I signaling, and assess ...
Ismail Yaz +13 more
wiley +1 more source
Objective Rheumatoid arthritis (RA) is characterized by anti‐modified protein antibodies (AMPAs), including anti‐citrullinated (ACPA), anti‐carbamylated (anti‐CarP), and anti‐acetylated (AAPA) protein antibodies. In contrast to other AMPAs, AAPA IgM is found in healthy individuals, raising questions about its role in early immune responses.
Aegli Athanasiadou +10 more
wiley +1 more source
Cross-sectional Study of Dermatitis Herpetiformis with Focus on Neurological Comorbidities. [PDF]
Malkovics T +5 more
europepmc +1 more source

